Takeda Pharmaceutical Co Ltd - Form 6-K Summary
Business Context and Reporting Period
This filing is a Form 6-K reporting the Quarterly Securities Report for the six-month period ended September 30, 2019 (FY2019 H1). The report covers the second quarter of the 143rd Business Term. The financial results are significantly impacted by the acquisition of Shire plc, which closed on January 8, 2019, and the adoption of IFRS 16 (Leases) effective April 1, 2019.
Key Financial Metrics
| Metric (JPY Millions) | Six Months Ended Sep 30, 2018 | Six Months Ended Sep 30, 2019 | Change |
|---|---|---|---|
| Revenue | 880,611 | 1,660,169 | +88.5% |
| Operating Profit | 171,956 | 50,310 | -70.7% |
| Net Profit | 126,489 | 33,280 | -73.7% |
| Net Profit Attributable to Owners | 126,668 | 33,184 | -73.7% |
| Basic EPS (JPY) | 161.76 | 21.32 | -86.8% |
| Net Cash from Operating Activities | 117,834 | 341,087 | +189.4% |
| Cash and Cash Equivalents (End of Period) | 317,080 | 543,517 | +71.4% |
| Total Assets | 4,274,839 | 12,880,141 | +201.3% |
| Total Liabilities | 2,102,678 (Est) | 8,010,457 | Significant Increase |
Note: Total Liabilities for 2018 H1 were not explicitly stated as a single line item in the summary table but can be derived from Assets minus Equity (2,172,161). The 2019 increase is driven by the Shire acquisition.
Material Changes vs. Prior Period
- Revenue Growth: Reported revenue increased 88.5% primarily due to the inclusion of Shire products (contributing 767.5 billion JPY). However, Underlying Revenue Growth (constant currency, excluding divestitures and non-recurring items) was flat at -0.2%.
- Profitability Decline: Operating profit dropped 70.7% and Net Profit dropped 73.7%. This was driven by:
- Amortization and impairment losses on intangible assets increasing to 273.7 billion JPY (up 466.7%), largely due to Shire acquisition accounting.
- Increased R&D expenses (up 52.1%) and SG&A expenses (up 57.4%) related to Shire integration.
- Higher net finance expenses (up 406.0%) due to debt assumed from Shire.
- Product Performance:
- GI: ENTYVIO sales grew 31.2% to 168.4 billion JPY.
- Rare Diseases: Underlying revenue decreased 10.5% due to competition and a recall of NATPARA. ADVATE sales declined 15.9%.
- Oncology: NINLARO sales grew 30.2% to 38.3 billion JPY. VELCADE sales declined due to generic entry in Europe.
- Neuroscience: Revenue surged 360.5% due to the inclusion of Shire's VYVANSE (131.5 billion JPY).
- Divestitures: Completed the sale of XIIDRA (July 2019) and Axcelead Drug Discovery Partners (April 2019). Agreements were also reached to divest OTC assets in the Middle East/Africa and Russia/CIS.
Guidance, Outlook, and Risks
- Underlying Metrics: Management highlights an Underlying Core Operating Profit Margin of 32.2% and Underlying Core EPS of 249.25 JPY, which exclude non-recurring items and purchase accounting effects.
- Swiss Tax Reform: A non-cash deferred tax benefit of 56.3 billion JPY was recorded due to new Swiss tax laws, significantly impacting the effective tax rate (220.8% vs 21.3% prior year) and net profit.
- R&D Pipeline: Key developments include FDA/EMA acceptance of subcutaneous ENTYVIO, approval of GATTEX for pediatric short bowel syndrome, and positive Phase 2 data for TAK-620 (maribavir). The TOURMALINE-AL1 trial for NINLARO in AL amyloidosis did not meet primary endpoints.
- Liquidity and Debt: Total bonds and loans decreased to 5,024.6 billion JPY due to redemptions and FX impacts. A new 700 billion JPY commitment facility was secured in September 2019.
- Risks: Risks include generic erosion (e.g., VELCADE, LIALDA), competitive pressure in Rare Hematology, and the success of post-merger integration.
Investor Verification Checklist
- Underlying vs. Reported: Verify the distinction between reported results (heavily impacted by Shire amortization) and underlying results (management's view of core performance).
- Shire Integration Costs: Monitor the trajectory of restructuring expenses and SG&A as integration progresses.
- Generic Erosion: Assess the long-term impact of generic entry on key products like VELCADE and LIALDA.
- Divestiture Timeline: Confirm the closing dates and financial impact of the pending OTC asset sales to Acino and STADA.
- Debt Servicing: Review the schedule for bond redemptions and the impact of interest rate fluctuations on finance expenses.